WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2007090862) NEUTRAL SPHINGOMYELINASE-3 AND ITS USE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2007/090862    International Application No.:    PCT/EP2007/051203
Publication Date: 16.08.2007 International Filing Date: 08.02.2007
Chapter 2 Demand Filed:    15.02.2008    
IPC:
C12N 9/16 (2006.01), A61K 45/00 (2006.01)
Applicants: KRÖNKE, Martin [DE/DE]; (DE).
KRUT, Oleg [DE/DE]; (DE).
KRÖNKE-WIEGMANN, Katja [DE/DE]; (DE).
HOPPE, Uta [DE/DE]; (DE)
Inventors: KRÖNKE, Martin; (DE).
KRUT, Oleg; (DE).
KRÖNKE-WIEGMANN, Katja; (DE).
HOPPE, Uta; (DE)
Agent: HELBING, Jörg; P.O. Box 10 22 41, 50462 Köln (DE)
Priority Data:
06101431.2 08.02.2006 EP
Title (EN) NEUTRAL SPHINGOMYELINASE-3 AND ITS USE
(FR) SPHINGOMYÉLINASE-3 NEUTRE ET UTILISATION DE CELLE-CI
Abstract: front page image
(EN)The present invention provides a neutral sphingomyelinase-3 (nSMase3), a nucleic acid encoding said nSMase3, a vector containing said nucleic acid, and cells and non- human organisms transformed or transfected with said nucleic acid sequence or vector. The invention furthermore relates to the use of said nSMase3 as pharmaceutical or diagnostic agent. Test systems for candidate active agents for their therapeutic potential in diseases connected with nSMase3 are also provided.
(FR)L'invention concerne une sphingomyélinase-3 neutre (nSMase3), un acide nucléique codant pour la nSMase3, un vecteur contenant cet acide nucléique, des cellules et des organismes non humains transformés ou transfectés au moyen de cette séquence d'acide nucléique ou de ce vecteur. L'invention concerne de plus l'utilisation de cette nSMase3 comme agent pharmaceutique ou comme agent diagnostique. L'invention concerne aussi des systèmes servant à tester le potentiel thérapeutique d'agents actifs candidats dans des maladies liées à la nSMase3.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)